Antiviral strategy turns on viral entry, replication, and host dependency
Viruses survive by hijacking host metabolism, and that dependence creates both the therapeutic opportunity and the therapeutic ceiling. Antiviral drugs can interrupt entry, replication, assembly, or release, yet no current agent fully eliminates every viral infection once the pathogen has established itself in host tissue. The review by Arumugam and colleagues places that reality at the center of modern antiviral development, using herpesviruses, influenza, hepatitis viruses, human immunodeficiency virus, and SARS-CoV-2 as the clearest examples of how biology dictates drug design.
The logic is straightforward. Viral replication is not a single event but a cascade, and each step depends on molecular interactions that can be blocked if the target is identifiable and accessible. Entry inhibitors, polymerase inhibitors, protease inhibitors, and immune-based interventions each interrupt a different point in the cycle. Even so, viral mutation, immune evasion, and intracellular residence keep many infections one step ahead of treatment, which is why the pipeline continues to expand beyond traditional small-molecule agents.
Herpes, influenza, hepatitis, and HIV remain the canonical test cases because each virus demands a different therapeutic architecture. Some depend heavily on surface attachment and membrane fusion, others on error-prone polymerases, and others on long-term persistence in host cells. The biologic diversity explains why one antiviral class rarely solves more than one disease family, and why broad-spectrum approaches remain difficult to sustain in practice.
COVID-19 accelerated interest in repurposing, immune therapy, and delivery science
The pandemic shifted antiviral thinking from incremental optimization to urgent repurposing. During COVID-19, attention widened beyond direct-acting antiviral drugs to include anticoagulants, convalescent plasma, and methods of preventing airborne spread. Each of these approaches reflects a different clinical problem: viral replication, thromboinflammation, passive immunity, and exposure control. In a respiratory virus with systemic consequences, treatment has to account for both the pathogen and the host response.
Convalescent plasma fits within that logic as a donor-derived immunologic tool, intended to transfer circulating antibodies to an infected patient. Anticoagulants address the coagulation disturbances that can complicate severe coronavirus disease. These are not substitutes for antiviral action, but they are part of the same therapeutic continuum when infection triggers endothelial injury, inflammatory activation, and thrombosis. The review treats those adjunctive measures as clinically relevant rather than peripheral, especially in the context of severe and evolving disease.
Airborne transmission also receives attention because prevention remains inseparable from treatment. Once a virus spreads efficiently through the air, downstream drug development cannot shoulder the entire burden. Infection control, vaccine deployment, and public health measures remain essential components of any antiviral response, particularly when variants alter transmission dynamics and clinical burden.
A single antiviral molecule is rarely enough when the virus spreads faster than the clinic can respond.
Nanotechnology is reshaping how antiviral agents reach their targets
Delivery has become as important as discovery. The review gives substantial attention to nanoparticles, nanoemulsions, nanogels, metal-based nanoparticles, and related carrier systems because poor bioavailability, unstable formulations, and limited tissue penetration can blunt even biologically active drugs. In principle, engineered carriers can improve solubility, prolong circulation time, concentrate drug at the site of infection, and reduce off-target exposure.
That idea extends into more speculative but increasingly discussed platforms: nanobubbles, nanofibers, nanodiamonds, nanotraps, and nanorobots. These are presented as future nanosystems with possible antiviral utility, not as established standards of care. Their appeal lies in precision. If a carrier can deliver an inhibitor directly to infected tissue or trap circulating virions before they reach host cells, then the effective antiviral dose may rise without a parallel increase in toxicity.
The review also considers micro- and nanoparticulates as part of the broader therapeutic toolkit. Such technologies are not merely engineering novelties; they are responses to a central pharmacologic problem in virology, where the target may be intracellular, the infection may be diffuse, and the immune environment may vary widely from patient to patient. Delivery platforms therefore function as enabling technologies for the next generation of antivirals rather than stand-alone cures.
Viral targets still define the limits of treatment
Across viral families, the target remains the decisive question. Entry blockers work only if the virus depends on a vulnerable receptor interaction. Polymerase inhibitors require a conserved enzyme architecture. Protease inhibitors depend on a cleavable viral polyprotein or analogous processing step. Vaccines, by contrast, do not directly inhibit replication; they preempt infection or blunt disease severity by training the immune system before exposure occurs. The review places these strategies side by side because successful control often requires more than one mechanism operating at once.
That framework is especially relevant for rapidly mutating viruses. Variant emergence can erode the activity of monoclonal antibodies and reduce the durability of immune escape-sensitive interventions. Vaccines still matter because they reduce the clinical impact of infection even when sterilizing immunity is incomplete, and because population-level protection lowers the number of severe cases that reach the hospital. In that setting, antiviral drugs remain indispensable for patients who become infected despite vaccination or who present with advanced disease.
Gene therapy appears in the review as another future-facing strategy. Its inclusion signals a broader ambition: not just suppressing acute replication, but redesigning host–virus interactions in a way that may be more durable than conventional pharmacology. The concept is still exploratory, yet it fits the central theme of the paper—viral disease is best confronted at multiple biological layers, not with a single intervention.
Environmental and translational questions remain attached to antiviral development
The review closes the loop by noting environmental implications of antivirals. Drug development does not end at the bedside. Manufacturing, distribution, persistence in the environment, and downstream ecological exposure can all influence how antiviral agents are deployed and regulated. Those concerns are easy to overlook during a pandemic, but they become unavoidable when medication use expands across millions of patients.
Clinical translation also remains uneven. Many of the approaches discussed in the review are promising in concept, but not every platform has equal evidence, and not every mechanism can be scaled safely or affordably. The challenge is to identify which viral targets are conserved enough for durable inhibition, which delivery systems can be manufactured at clinical scale, and which vaccine or immune-based strategies retain value as pathogens evolve.
For now, the most defensible reading of the field is pragmatic. Traditional antivirals still matter, vaccines remain central, and adjunctive therapies such as anticoagulants and passive immunotherapy have a role in selected settings. New delivery systems may widen the therapeutic window, but they must prove that they can improve outcomes beyond theoretical elegance. The next phase of antiviral progress will depend less on conceptual variety than on whether these approaches can survive real-world virology, resistance, toxicity, and logistics.